Becton Dickinson & Co
BDX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$878.00 | Ydwctdc | Thvlhfdhp |
Becton, Dickinson's Core Business on Solid Trajectory
Business Strategy and Outlook
After a tumultous few years, Becton, Dickinson is undergoing course correction. The COVID-19 revenue windfall has been reinvested, which should lift the firm's core business growth in the upcoming years once the testing revenue fades. The biggest uncertainty remains around the return of BD's pump infusion system (Alaris) to the market, which could be a material catalyst for the company whenever it occurs.